Karyopharm to Participate at 11th Annual SVB Leerink Global Healthcare Conference

Rhea-AI Summary

Karyopharm Therapeutics (Nasdaq: KPTI), a leader in cancer therapies, announced that CEO Richard Paulson will participate in a virtual fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022, at 1:40 p.m. ET. A live webcast will be available in the Investor section of their website, with replays accessible for 90 days. Karyopharm specializes in oral Selective Inhibitor of Nuclear Export (SINE) technology, including its approved drug XPOVIO®. The company's pipeline targets multiple high unmet need cancer indications.

NEWTON, Mass., Feb. 11, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Richard Paulson, President and Chief Executive Officer of Karyopharm, will participate in a fireside chat at the 11^th Annual SVB Leerink Global Healthcare Conference. The conference is being conducted in a virtual format and the fireside chat will take place on Friday, February 18, 2022 at 1:40 p.m. ET.

A live webcast of the fireside chat, along with accompanying slides, can be accessed under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations, and will be available for replay for 90 days following the event. 

About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company pioneering novel cancer therapies. Since its founding, Karyopharm has been the industry leader in oral Selective Inhibitor of Nuclear Export (SINE) compound technology, which was developed to address a fundamental mechanism of oncogenesis: nuclear export dysregulation. Karyopharm's lead SINE compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications and has received regulatory approvals in various indications in a growing number of ex-U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO®) and China. Karyopharm has a focused pipeline targeting multiple high unmet need cancer indications, including in endometrial cancer, myelodysplastic syndromes and myelofibrosis. For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on Twitter at @Karyopharm and LinkedIn.

XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc. Any other trademarks referred to in this release are the property of their respective owners.

View original content:https://www.prnewswire.com/news-releases/karyopharm-to-participate-at-11th-annual-svb-leerink-global-healthcare-conference-301480432.html

SOURCE Karyopharm Therapeutics Inc.

FAQ

When will Karyopharm Therapeutics participate in the SVB Leerink Global Healthcare Conference?

Karyopharm Therapeutics will participate in the SVB Leerink Global Healthcare Conference on February 18, 2022, at 1:40 p.m. ET.

Who is speaking on behalf of Karyopharm at the healthcare conference?

Richard Paulson, President and CEO of Karyopharm, will speak at the conference.

Where can I watch the Karyopharm conference fireside chat?

The fireside chat can be accessed via a live webcast in the Investor section of Karyopharm's website.

How long will the Karyopharm fireside chat be available for replay?

The replay of the Karyopharm fireside chat will be available for 90 days after the event.

What is Karyopharm Therapeutics known for?

Karyopharm is known for pioneering novel cancer therapies, particularly its oral Selective Inhibitor of Nuclear Export (SINE) compounds.

What is XPOVIO® and its significance to Karyopharm?

XPOVIO® is Karyopharm's first-in-class, oral exportin 1 (XPO1) inhibitor, used in multiple oncology indications.